Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journal

4 Scopus Citations
View graph of relations

Author(s)

  • Xin Li
  • Yizhe Wu
  • Gaofei Tian
  • Yixiang Jiang
  • Zheng Liu
  • Xianbin Meng
  • Xiuchong Bao
  • Haiteng Deng
  • Xiang David Li

Detail(s)

Original languageEnglish
Pages (from-to)11497−11505
Journal / PublicationJournal of the American Chemical Society
Volume141
Issue number29
Online published27 Jun 2019
Publication statusPublished - 24 Jul 2019

Abstract

Bromodomains, epigenetic “readers” of lysine acetylation marks, exist in different nuclear proteins with diverse biological functions in chromatin biology. Malfunctions of bromodomains are associated with the pathogenesis of human diseases, such as cancer. Bromodomains have therefore emerged as therapeutic targets for drug discovery. Given the high structural similarity of bromodomains, a critical step in the development of bromodomain inhibitors is the evaluation of their selectivity to avoid off-target effects. While numerous bromodomain inhibitors have been identified, new methods to evaluate the inhibitor selectivity toward endogenous bromodomains in living cells remain needed. Here we report the development of a photoaffinity probe, photo-bromosporine (photo-BS), that enables the wide-spectrum profiling of bromodomain inhibitors in living cells. Photo-BS allowed light-induced cross-linking of recombinant bromodomains and endogenous bromodomain-containing proteins (BCPs) both in vitro and in living cells. The photo-BS-induced labeling of the bromodomains was selectively competed by the corresponding bromodomain inhibitors. Proteomics analysis revealed that photo-BS captured 28 out of the 42 known BCPs from the living cells. Assessment of the two bromodomain inhibitors, bromosporine and GSK6853, resulted in the identification of known as well as previously uncharacterized bromodomain targets. Collectively, we established a chemical proteomics platform to comprehensively evaluate bromodomain inhibitors in terms of their selectivity against endogenous BCPs in living cells.

Citation Format(s)

Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells. / Li, Xin; Wu, Yizhe; Tian, Gaofei; Jiang, Yixiang; Liu, Zheng; Meng, Xianbin; Bao, Xiuchong; Feng, Ling; Sun, Hongyan; Deng, Haiteng; Li, Xiang David.

In: Journal of the American Chemical Society, Vol. 141, No. 29, 24.07.2019, p. 11497−11505.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journal